肠道菌群:急性胰腺炎治疗的新视角与临床应用前景
急性胰腺炎是以胰腺组织自身消化和炎症反应为特征的严重炎症性疾病,近期研究揭示肠道菌群与急性胰腺炎存在密切关联。肠道菌群是由数万亿微生物组成的复杂生态系统,与宿主代谢过程、免疫系统调节和肠道结构维持等多种生理活动密切相关。在急性胰腺炎患者中,肠道菌群失调被认为在疾病发生和进展中起关键作用,不仅损害肠道屏障完整性,还可能通过多种机制加剧炎症反应,从而影响疾病严重程度和患者临床预后。本文综述了肠道菌群在急性胰腺炎中的作用机制,探讨菌群失调如何影响疾病进展,并评估当前调节肠道菌群的临床治疗方法,包括益生菌补充、粪菌移植、抗生素治疗和早期肠内营养,同时讨论上述治疗方法的疗效与安全性并概述未来研究方向。
要点
- 急性胰腺炎患者存在肠道菌群失调,菌群失调被认为在疾病发生和进展中起关键作用,并可能影响疾病严重程度和患者临床预后。
- 菌群失调不仅损害肠道屏障完整性,还可能通过多种机制加剧炎症反应。
- 本文评估的调节肠道菌群治疗方法包括益生菌补充、粪菌移植、抗生素治疗和早期肠内营养。
- 文章讨论了上述治疗方法的疗效与安全性,并概述了未来研究方向。
- 深入理解肠道菌群与急性胰腺炎的相互作用,有望开发更精准、个体化的治疗方案以改善患者生活质量和临床结局。
适用人群与场景
- 急性胰腺炎患者。
处置流程与药物剂量
- 调节肠道菌群的临床治疗方法包括益生菌补充、粪菌移植、抗生素治疗和早期肠内营养。
研究设计与关键结果
- 综述指出肠道菌群失调被认为在急性胰腺炎发生和进展中起关键作用,不仅损害肠道屏障完整性,还可能通过多种机制加剧炎症反应,从而影响疾病严重程度和患者临床预后。
- 文章评估了益生菌补充、粪菌移植、抗生素治疗和早期肠内营养等调节肠道菌群治疗方法的疗效与安全性。
证据类型、等级与局限
- 证据类型:综述。
- 局限:原文未报告局限性。
指南或共识出处
- Zhonghua Wei Zhong Bing Ji Jiu Yi Xue
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「对床旁实践的改变」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Acute pancreatitis (AP) is a severe inflammatory disease characterized by self-digestion of pancreatic tissue and inflammatory responses. Recent studies have revealed a close connection between gut microbiota and AP. The gut microbiota community, a complex ecosystem composed of trillions of microorganisms, is closely associated with various physiological activities of the host, including metabolic processes, immune system regulation, and intestinal structure maintenance. However, in patients with AP, dysbiosis of the gut microbiota are believed to play a key role in the occurrence and progression of the disease. This dysbiosis not only impairs the integrity of the intestinal barrier, but may also exacerbate inflammatory responses through multiple mechanisms, thereby affecting the severity of the disease and patient' clinical prognosis. This article reviews the mechanisms of action of gut microbiota in AP, explores how gut microbiota dysbiosis affects disease progression, and evaluates current clinical treatment methods to regulate intestinal flora, including probiotic supplementation, fecal microbiota transplantation, antibiotic therapy, and early enteral nutrition. In addition, this article discusses the efficacy and safety of the aforementioned therapeutic approaches, and outlines future research directions, aiming to provide novel perspectives and strategies for the diagnosis, treatment and prognostic evaluation of AP. Through in-depth understanding the interaction between gut microbiota and AP, it is expected that more precise and personalized therapeutic regimens will be developed to improve patients' quality of life and clinical outcomes.
参考来源
- Lang Q, Zeng Y, Yao H, et al. [Gut microbiota: new perspective on the treatment of acute pancreatitis and clinical application prospects]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2025. PMID: 41146499. doi:10.3760/cma.j.cn121430-20240903-00744
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。